Spots Global Cancer Trial Database for Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Official Title: A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast

Study ID: NCT00039520

Conditions

Breast Cancer

Interventions

docetaxel

sulindac

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastatic or recurrent breast cancer.

Detailed Description: OBJECTIVES: * Determine the response rate of women with metastatic or recurrent adenocarcinoma of the breast treated with sulindac and docetaxel. * Determine the time to progression of patients treated with this regimen. * Determine the toxicity of this regimen in these patients. OUTLINE: Patients receive oral sulindac twice daily. Patients also receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed within 3-4 weeks. PROJECTED ACCRUAL: Approximately 12-33 patients will be accrued for this study.